氨甲环酸在关节置换手术围手术期的应用

注册号:

Registration number:

ChiCTR-IPR-15005884 

最近更新日期:

Date of Last Refreshed on:

2015-01-26 07:05:43 

注册时间:

Date of Registration:

2015-01-25 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

氨甲环酸在关节置换手术围手术期的应用

Public title:

Tranexamic acid used in joint replacement operation in perioperative period

注册题目简写:

English Acronym:

研究课题的正式科学名称:

氨甲环酸在关节置换手术围手术期的应用

Scientific title:

Tranexamic acid used in joint replacement operation in perioperative period

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

岳勇 

研究负责人:

岳勇 

Applicant:

Yue Yong 

Study leader:

Yue Yong 

申请注册联系人电话:

Applicant telephone:

+86 18999505353

研究负责人电话:

Study leader's
telephone:

+86 18999505353

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yueyong54321@qq.com

研究负责人电子邮件:

Study leader's E-mail:

yueyong54321@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

新疆克拉玛依市人民医院

研究负责人通讯地址:

新疆克拉玛依市人民医院

Applicant address:

People's Hospital of Karamay City, Xinjiang

Study leader's address:

People's Hospital of Karamay City, Xinjiang

申请注册联系人邮政编码:

Applicant postcode:

834000

研究负责人邮政编码:

Study leader's postcode:

834000

申请人所在单位:

新疆克拉玛依市人民医院

Applicant's institution:

People's Hospital of Karamay City, Xinjiang

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

新疆克拉玛依市人民医院

Primary sponsor:

People's Hospital of Karamay City, Xinjiang

研究实施负责(组长)单位地址:

新疆克拉玛依市人民医院

Primary sponsor's address:

People's Hospital of Karamay City, Xinjiang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

新疆维吾尔自治区

市(区县):

Country:

China

Province:

Xinjiang Uygur Autonomous Region

City:

单位(医院):

克拉玛依市人民医院

具体地址:

克拉玛依市人民医院

Institution
hospital:

People's Hospital of Karamay City

Address:

People's Hospital of Karamay City

经费或物资来源:

克拉玛依市财政拨款

Source(s) of funding:

Karamay City Funding

研究疾病:

氨甲环酸在关节置换手术围手术期的应用  

Target disease:

Tranexamic acid used in joint replacement operation in perioperative period

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

全膝关节置换术作为一项日益成熟的外科技术,使得关节病患者提高了生活质量,围手术期总失血量多在700ml-2000ml;输血比例较高。因此,如何减少手术后的出血及减少输血风险越来越重要。氨甲环酸(Tranexamic Acid TXA)是一种人工合成的抗纤溶药,可有效减少出血及输血率,但氨甲环酸理论上可能导致纤溶酶系统活性相对不足,致血栓溶解减少而增加深静脉血栓及肺栓塞的风险。 目前临床上的应用方法:静脉及局部使用TXA。 局部应用氨甲环酸的效果如何?哪一种使用方式效果更好?减少出血及输血率,同时并不增加DVT的风险?目前缺乏高质量的研究结果来证实。因此,比较这两种方法,从而筛选合适有效的全膝关节置换术止血方法,为制定围手术期综合止血方案提供客观依据。  

Objectives of Study:

Total knee arthroplasty is an increasingly mature surgical technique, which makes the joint disease in patients with improved quality of life, peri operation period of total blood loss more than in the 700ml-2000ml; a higher proportion of blood transfusion. Therefore, how to reduce bleeding after operation and reduce the risk of blood transfusion is becoming more and more important. Tranexamic acid (Tranexamic Acid TXA) is a synthetic antifibrinolytic drugs, can effectively reduce the bleeding and blood transfusion rate, but the tranexamic acid theory may lead to a relative shortage of fibrinolytic system activity, thrombus dissolution decreased risk of deep vein thrombosis and pulmonary embolism. Methods clinical application at present: intravenous and local TXA. How to topical application of tranexamic acid effect? What kind of way to use better? To reduce bleeding and blood transfusion rate, at the same time does not increase the risk of DVT? The current lack of results of high quality to confirm. Therefore, a comparison of the two methods, and screening of total knee arthroplasty hemostatic methods are appropriate and effective, and provide objective basis for formulating integrated scheme of perioperative hemostasis.

药物成份或治疗方案详述:

氨甲环酸 

Description for medicine or protocol of treatment in detail:

Tranexamic acid 

纳入标准:

Inclusion criteria

排除标准:

1)既往发生过DVT;
2)有使用TXA的禁忌:包括有血栓形成倾向的房颤患者、支架植入术后患者、安置心脏起搏器的患者等;
3)凝血功能紊乱;合并严重凝血功能障碍、活动性胃溃疡或正在接受抗凝药物治疗的患者
4)TXA过敏;
5)严重心、肺、肝、肾功能不全的患者。
6)身体质量指数 ( body mass index ,B M I )大于 35
7)双侧膝关节OA 或 拟行膝关节人工关节翻修术的患者 。

Exclusion criteria:

1) had had a previous DVT;
2) use TXA taboo: including the tendency of thrombosis in patients with atrial fibrillation, stent implantation, patients with pacemaker implantation patients;
3) blood coagulation function disorder; combined with severe coagulopathy, active gastric ulcer or are receiving anticoagulant treatment in patients with;
4) TXA allergy;
5) serious heart, lung, liver, renal insufficiency patients;
Body mass index;
6) body mass index (BMI) is greater than 35;
7) bilateral knee OA or undergoing knee artificial revision arthroplasty patients.

研究实施时间:

Study execute time:

From 2015-01-01 00:00:00 To 1990-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2015-01-01 00:00:00 To 2016-01-31 00:00:00

干预措施:

Interventions:

组别:

局部用氨甲环酸组

样本量:

40

Group:

The local use of tranexamic acid group

Sample size:

干预措施:

局部用氨甲环酸

干预措施代码:

Intervention:

The local use of tranexamic acid

Intervention code:

组别:

静脉用氨甲环酸组

样本量:

40

Group:

Tranexamic acid group with vein

Sample size:

干预措施:

静脉用氨甲环酸

干预措施代码:

Intervention:

Tranexamic acid with vein

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

新疆维吾尔自治区 

市(区县):

 

Country:

China

Province:

The Xinjiang Uygur Autonomous Region

City:

单位(医院):

克拉玛依市人民医院 

单位级别:

三甲医院 

Institution
hospital:

People's Hospital of Karamay City

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

失血量

指标类型:

主要指标

Outcome:

Blood loss

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血红蛋白

指标类型:

主要指标

Outcome:

Hb

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由单独一人操作、spss12.0软件产生随机顺序,随机方案事先完成,装入采用密闭的信封封存,通过封存的密闭信封进行分配隐藏。所有的信封表面仅标明医院名称以及随机的数字号。(新疆医科大学1附院骨科完成)

Randomization Procedure (please state who generates the random number sequence and by what method):

The random sequence generated by a separate operation, SPSS12.0 software, random plan completed in a envelope

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

由单独一人操作、spss12.0软件产生随机顺序,随机方案事先完成,装入采用密闭的信封封存,通过封存的密闭信封进行分配隐藏。所有的信封表面仅标明医院名称以及随机的数字号。(新疆医科大学1附院骨科完成),新疆医科大学1附院骨科产生分配顺序,克拉玛依市人民医院骨科登记受试者,克拉玛依市人民医院骨科将受试者分配。受试者、实施干预者、结果评定者事先无法知道分组情况

Blinding:

only marked name of hospital and random numbers. (the 1 Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University 1 Affiliated Hospital Department of orthopedics department of orthopedics) generated the allocation sequence, Karamay City Peoples Hospital Department of orthopedics registration subjects, Department of orthopedics, peoples Hospital of Karamay subjects distribution. The subjects, intervention, evaluation result cannot know beforehand group

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

新疆克拉玛依市人民医院

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Peoples Hospital of Karamay City, Xinjiang

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

新疆克拉玛依市人民医院

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Peoples Hospital of Karamay City, Xinjiang

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2015-01-26 07:05:43